argenx to report half year 2020 financial results and second quarter business update on July 30, 2020

On July 23, 2020 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, reported that it will host a conference call and audio webcast on Thursday, July 30, 2020 at 2:30 pm CET (8:30 am ET) to discuss its second quarter 2020 financial results and provide a business update (Press release, argenx, JUL 23, 2020, View Source [SID1234562297]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please select your phone number below and use the confirmation code 7470386. The webcast may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for 90 days following the call.

Synaffix Announces Third Deal Expansion by ADC Therapeutics

On July 23, 2020 Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, reported that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies (Press release, Synaffix, JUL 23, 2020, View Source [SID1234562267]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs, which brings the total number of programs using Synaffix’ ADC technologies to five. ADC Therapeutics also gains access to the latest innovative extensions of Synaffix’ proprietary GlycoConnect platform, including DAR1 technology that enables stable attachment of just a single drug per antibody.

Synaffix is eligible to receive upfront, milestone and royalty payments tied to each program. Further financial details are not disclosed.

Peter van de Sande, CEO of Synaffix said:

"We are very pleased to see the rapid progression of ADC Therapeutics’ programs that have been developed using our GlycoConnect ADC technology platform, and the multiple collaboration expansions that have followed our original agreement.

"We look forward to continuing to work closely with the ADC Therapeutics team as they translate more product candidates using GlycoConnect into the clinic."

Synaffix entered into the original commercial license agreement with ADC Therapeutics in October 2016. ADC Therapeutics is responsible for the research, development, manufacturing and commercialization of any resulting ADC products, and Synaffix is responsible for the manufacturing of components specifically related to its proprietary ADC technologies.

BioCryst to Report Second Quarter 2020 Financial Results on August 6

On July 23, 2020 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020 (Press release, BioCryst Pharmaceuticals, JUL 23, 2020, https://ir.biocryst.com/news-releases/news-release-details/biocryst-report-second-quarter-2020-financial-results-august-6 [SID1234562298]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 5142479. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 5142479.

IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C

On July 23, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported an update on the ongoing development of its product candidates, eftilagimod alpha ("efti" or "IMP321") and IMP761, the activity of its partners, and the minimal impacts to the business from the COVID-19 pandemic (Press release, Immutep, JUL 24, 2020, View Source [SID1234562316]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Protecting the health of patients recruited into our clinical trials and our employees continues to be a focus for Immutep during the COVID-19 pandemic. Pleasingly, none of our employees have been infected with the virus. We have also been working closely with the clinical sites and regulators to monitor the situation and make any necessary adjustments to trial protocols to diminish risks to patients.

To date, the Company has not seen a significant impact on the pace of trial recruitment for its two actively recruiting trials: TACTI-002 and INSIGHT-004. TACTI-002 is now 74% recruited and INSIGHT-004 reached full recruitment during the quarter. AIPAC has been fully recruited since June 2019.

Eftilagimod Alpha Clinical Update

TACTI-002 – Phase II clinical trial

TACTI-002 is evaluating the combination of efti with KEYTRUDA (pembrolizumab) in up to 109 patients with second line HNSCC or NSCLC in first and second line.

During the quarter, Immutep has continued to report consistently encouraging findings from its TACTI-002 study. The most recent results presented at ASCO (Free ASCO Whitepaper) in June reported the first Complete Response (complete disappearance of target lesion) from a patient with second line HNSCC (Part C). The Overall Response Rate according to iRECIST (iORR) of this group is 38.9% and 44% of patients were still under therapy. For patients with first line NSCLC (Part A) progression-free survival (PFS) is estimated to be more than 9 months, which is a very encouraging achievement for patients with such advanced cancer. The iORR for this group is 53% and 71% of patients had tumour shrinkage. Most importantly, responses have been observed regardless of the PD-L1 expression status. The trial continues to report a good safety profile from the combination. Recruitment for Part A of the study has recently been completed, while recruitment is ongoing for Part B (second line NSCLC) and for stage 2 of Part C (second line HNSCC). In total, 81 patients out of up to 109 patients (74%) are already enrolled and participating in the trial.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

LOGO

Further results are expected to be reported throughout calendar year 2020.

AIPAC – Phase IIb clinical trial

AIPAC is evaluating efti in combination with paclitaxel, a standard of care chemotherapy, in patients with metastatic breast cancer. Following the read out of PFS data from AIPAC in March 2020, Immutep has continued to explore the favourable results demonstrated in multiple predefined patient subgroups in greater detail. Overall, the PFS results showed that efti provided an improvement for patients compared to the placebo group at the 6-month landmark and an increase in ORR of 48.3% compared to 38.4% in the placebo group.

Importantly, Overall Survival (OS) results are expected to be reported from AIPAC by the end of calendar year 2020.

INSIGHT-004 – Phase I clinical trial

INSIGHT-004 is evaluating the combination of efti with avelumab, a human anti-PD-L1 antibody, in 12 patients with different advanced solid malignancies, primarily gastrointestinal indications. It is the 4th arm of the ongoing INSIGHT Phase I clinical trial which is being conducted by trial sponsor, the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany ("IKF").

In April 2020, INSIGHT-004 reached full recruitment and first data was reported in May 2020. Encouraging early efficacy signals have been observed in a variety of cancer indications and, overall, Partial Responses have been reported in 4 of the 12 patients. Importantly, thus far, the combination treatment of efti and avelumab is safe and well tolerated.

Further data from the study is expected to be reported throughout calendar year 2020.

Efti Manufacturing

The Company plans to manufacture two new 200L batches of efti in FY21 which will provide sufficient material to complete the current clinical program. During the quarter, Immutep postponed its efti up-scaling manufacturing program at the WuXi Biologics manufacturing plant (Wuxi, China). The program aims to upscale the manufacturing process from 200L to 2,000L single-use bioreactors to prepare for potential commercial manufacturing and additional registration trials in multiple indications. Immutep will recommence the 2000L manufacturing program as its clinical development program for efti advances.

Separately, Immutep’s partner in China, EOC Pharma, has started upscaling manufacturing for efti to 2,000L.

IMP761 Preclinical Update

IMP761 is an immunosuppressive agonist antibody to LAG-3 for the treatment of autoimmune diseases, such as inflammatory bowel diseases, rheumatoid arthritis, and multiple sclerosis. The Company’s manufacturing partner for IMP761, Batavia Biosciences, reported significant progress in the cell line development of IMP761, delivering a pharmaceutical-grade, stable CHO cell line that produces sufficient yields for clinical development. The program is now working on the completion of the cell line development.

Partner Updates

EOC Pharma

Immutep’s partner and Chinese licensee, EOC Pharma, is evaluating efti (designated as EOC202 in China) in patients with metastatic breast cancer in a Phase I study in China, called EOC202A1101.

During the quarter, EOC Pharma confirmed its plans to continue advancing efti through clinical trials following its analysis of the PFS data, including subgroup analysis, from Immutep’s Phase IIb AIPAC study, detailed above. This includes manufacturing scale up work, also detailed above.

CYTLIMIC

CYTLIMIC is evaluating efti in two Phase I clinical trials as part of a therapeutic vaccine, known as CYT001, in patients with advanced or metastatic solid cancer.

In June 2020, CYTLIMIC reported interim results from its second Phase I study in the neoadjuvant setting before surgery, called YCP02, showing that tumour cell death and infiltration of CD8 T cells into hepatocellular carcinoma surgical samples was observed in 6 out of 9 patients.

GSK

Clinical Proof-of-Concept data is expected in 1H of calendar year 2021 from GSK’s ongoing Phase II trial of GSK’781 in ulcerative colitis.

Financials

Cash receipts from customers for the quarter were $0.13 million, compared to $0.22 million in Q3 FY2020. Cash receipts from government grants and tax incentives for the quarter were $5.1 million, compared to nil in Q3 FY2020.

The net cash used in G&A activities in the quarter was $0.36 million compared to $0.49 million in Q3 FY2020. G&A costs for the quarter includes $171K in payment of Non-Executive Director’s fees and Executive Director’s salary.

Total net cash inflows from operating activities in the quarter was $0.12 million. In comparison, total net cash outflows used in the operating activities in Q3 FY2020 were $6.09 million.

The net cash used in Research and Development activities in the last quarter was $3.77 million, compared to $4.71 million in Q3 FY2020. R&D expenditure is expected to continue to decline further over the remaining two quarters of this calendar year as almost all patients in the AIPAC Phase IIb clinical trial have completed the treatment and moved into the follow-up phase.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

In April 2020, Immutep raised A$12 million before transaction costs via a Placement. The proceeds are being used to continue the LAG-3 related programs, including the ongoing clinical development of efti and the development of IMP761.

The cash balance as at 30 June 2020 was $26.3 million compared to a balance of $16.1 million as at 31 March 2020. The Company’s cash runway is expected to extend beyond several significant data catalysts to the end of calendar year 2021.

A copy of the Appendix 4C – Quarterly Cash Flow Report for the quarter is attached.

St. Baldrick’s Foundation awards grants to Case Western Reserve for pediatric cancer research

On July 23, 2020 Cancer researchers Alex Huang, Reshmi Parameswaran and Yamilet Huerta reported that have been awarded $315,000 in grants from the St. Baldrick’s Foundation to conduct research of new immunotherapy treatments for pediatric cancers (Press release, Case Western Reserve University, JUL 23, 2020, View Source [SID1234562373]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Huang, professor of pediatrics at Case Western Reserve University School of Medicine and co-leader of the Hematopoietic and Immune Cancer Biology Program of the Case Comprehensive Cancer Center (CCCC), received both a research grant and funding support for a summer research fellow in his laboratory.

Huang was awarded a one-year grant to begin development of a novel biomarker that would predict clinical response for advanced muscle tumor, Rhabdomyosarcoma, using immunotherapy through cryoablation—a procedure during which ultra-cold liquid nitrogen is used to kill tumor cells and activate the patient’s immune system.

"Treatment for Rhabdomyosarcoma is aggressive, but patient outcomes are the least improved in childhood cancer," said Huang. "With this grant, we hope to find the data we need to rapidly move from the lab to a clinical trial, making an impact for patients in the near future."

Melissa Bonner, a second-year Medical Scientist Training Program (MSTP) student who started her PhD thesis work in Huang’s laboratory this summer, received a summer fellowship to investigate a class of novel drugs that targets a tumor-specific carbonic anhydrase and disrupts a sarcoma tumor’s ability to manipulate its tissue environment, thereby making immunotherapy more effective.

Parameswaran and Huerta each received funding to continue projects to create better treatments for acute myeloid leukemia (AML), the second-most common form of acute leukemia in children.

Parameswaran is an assistant professor in the Division of Hematology and Oncology at the School of Medicine and member of the Hematopoietic and Immune Cancer Biology Program at the CCCC. She received a fifth year of funding for her St. Baldrick’s Scholar Award to continue to develop a new immunotherapy strategy using Natural Killer (NK) cells, a type of white blood cells with potential to kill cancer cells. Parameswaran in developing a new potential therapy where NK cells from a patient are isolated in a lab and expanded to enhance cancer-fighting potential, then injected back into the patient to kill childhood AML cells.

Photo of Reshmi Parameswaran
Reshmi Parameswaran
"Successful completion of this research will lead to new clinical trials using activated NK cells as an adoptive immunotherapy for pediatric AML," said Parameswaran.

Huerta, an instructor of pediatrics at the School of Medicine, a member of the Huang lab and a pediatric hematology/oncology fellow at University Hospitals Rainbow Babies & Children’s Hospital, was awarded additional fellow funding to continue her study of the use of targeted immunotherapy in future clinical trials to treat AML. She is engineering T-cells that are capable of binding to a specific target on AML cells while "engaging" neighboring T-cells, mounting an immune response and killing cancer cells.

Photo of Yamilet Huerta in the lab
Yamilet Huerta
Huerta said prognosis of a child with AML can remain poor even with chemotherapy and stem-cell treatment, but she sees promise in manipulating T-cells that are naturally part of the body’s immune system to eradicate chemo-resistant tumor cells.

The St. Baldrick’s Foundation is a volunteer-driven charity committed to funding the most promising research to find cures for childhood cancers and give survivors long and healthy lives. The Foundation is the largest private funder of childhood cancer research grants and awarded new grants totaling more than $12.9 million in its summer grant cycle to support the brightest minds in the pediatric cancer field. The round of grants supports the best research at 36 institutions nationally. The Foundation has given the School of Medicine and University Hospitals Rainbow Babies & Children’s Hospital more than $5.4 million to support childhood cancer research.